MedTrace Logo

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients

NCT01408602 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2014-05-12

No results posted yet for this study

Summary

This study will treat moderate to severe rheumatoid arthritis with MRC375 (either 75 mg 3 times a day, 150 mg 3 times a day or placebo 3 times a day)in patients 18 years of age or older that can be currently on low doses of methotrexate or can stop treatment of current RA medications to enter the study. Safety of MRC375 will also be evaluated. There are up to 8 clinic visits over 24 weeks.

Conditions

Interventions

DRUG

MRC375

MRC 375 (enteric coated Tetracycline) 75mg 3 times a day for 24 weeks.

DRUG

Matching Placebo

Matching Placebo 3 times a day for 24 weeks. Early escape at week 16,20.

DRUG

MRC375 150mg

MRC375 (enteric coated Tetracycline) 150mg 3 times a day for 24 weeks

Sponsors & Collaborators

  • Camargo Pharmaceutical Services

    collaborator INDUSTRY

  • Clin Data Services

    collaborator UNKNOWN

  • Harrison Clinical Research

    collaborator INDUSTRY

  • BARC Global Central Laboratory

    collaborator UNKNOWN

  • Bilcare Global Clinical Supplies

    collaborator UNKNOWN

  • Molecular Research Center, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01408602 on ClinicalTrials.gov